false
0001235912
0001235912
2025-08-04
2025-08-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 4, 2025
CVRx,
Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-40545 |
|
41-1983744 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
9201
West Broadway Avenue, Suite 650
Minneapolis,
MN 55445
(Address of principal executive offices) (Zip
Code)
(763)
416-2840
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
stock, par value $0.01 per share |
|
CVRX |
|
The Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On August 4, 2025, CVRx, Inc. (the “Company”)
issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1,
is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section
and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 4, 2025, the
Company announced that its Board of Directors (the “Board”) appointed Brent Binkowski as Chief Operating Officer, effective
August 11, 2025.
Mr. Binkowski, age 56, previously served as Vice President of
Operations – Interventional Urology of Coloplast Corp., a healthcare products company, from June 2020 to August 2025. Prior to Coloplast,
Mr. Binkowski held positions of increasing responsibility in engineering, manufacturing and operations at Teleflex Incorporated, Vascular
Solutions, Inc. (which was acquired by Teleflex), CeloNova BioSciences, Inc., and American Medical Systems – Ireland. The Compensation
Committee of the Board approved the following compensation for Mr. Binkowski: (i) an initial annual base salary of $405,000, (ii) a target
cash incentive award of 50% of base salary (which will be pro-rated for fiscal 2025), (iii) initial equity awards consisting of 74,900
stock options and 16,600 restricted stock units, which will have terms consistent with the Company’s current forms of equity awards,
and (iv) a sign-on bonus in recognition of the annual incentive opportunity he will forfeit from his current employer in the amount of
$50,000 that is subject to repayment if Mr. Binkowski resigns or is terminated for cause prior to the first anniversary of his hire date.
Mr. Binkowski will receive the Company’s standard form of severance agreement for executive officers.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits
Exhibit
No. |
|
Description |
| 99.1 |
|
Press release of CVRx, Inc., dated August 4, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
CVRx, Inc. |
| |
|
| Date: August 4, 2025 |
By: |
/s/ Jared Oasheim |
| |
|
Name: Jared Oasheim |
| |
|
Its: Chief Financial Officer |
